C4 therapeutics announces positive data from cft7455 phase 1 trial in relapsed/refractory multiple myeloma

Data support 14 days on/14 days off as optimal dosing schedule; cft7455 is well tolerated with promising signs of anti-myeloma activity

CCCC Ratings Summary

CCCC Quant Ranking